… of tapinarof cream 1% leading to this first approval for the topical treatment of plaque psoriasis.
… Tapinarof cream 1% (VTAMA ® ) was approved in May 2022 in the USA for the topical …

… Tapinarof cream 1% (VTAMA ® ; Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl
… ) to treat plaque psoriasis in adults and under investigation for the treatment of psoriasis in …

… A novel topical treatment named tapinarof (GSK2894512, DMVT-505, VTAMA™) has been
… of plaque psoriasis in adults. Citation5 Here, we review the clinical utility of tapinarof (ie, …

… 3 trials [9] and the PSOARING 3 open-label long-term extension trial [10], tapinarof (VTAMA
® ) cream 1% has been approved in the USA and is indicated for the topical treatment of …

… This article reviews the efficacy and safety of 1% tapinarof cream for plaque psoriasis. …
and safety of 1% tapinarof cream in patients with chronic plaque psoriasis. Criteria for inclusion …

… tapinarof’s mechanism in treating plaque psoriasis. Subsequently, it examines the effectiveness
and safety of tapinarof 1% cream … Administration (FDA) approved tapinarof (VTAMA®), a …

… analysis of patients with plaque psoriasis initiating tapinarof cream 1% QD in the “… tapinarof
cream have comorbidity profiles consistent with the general population with plaque psoriasis …

… of tapinarof cream 1% QD was safe and efficacious for up to 1 year in patients with mild to
severe psoriasis. … Consequently, tapinarof cream 1% QD may represent a novel, nonsteroidal …

… Tapinarof cream 1% (VTAMA) once daily is effective and well tolerated in adults with mild
to severe plaque psoriasis. Tapinarof is not a steroid cream and works in a unique way to treat …

… Tapinarof cream 1% QD demonstrated rapid onset of clinically meaningful efficacy as early
as Week 1, with continued improvement through Week 12, in patients with plaque psoriasis …